Nemolizumab Market Drug Insight and Market Forecast - 2032

Nemolizumab Market Drug Insight and Market Forecast − 2032

“Nemolizumab Market Drug Insight and Market Forecast – 2032” report provides comprehensive insights about nemolizumab for Atopic Dermatitis (AD) in the seven major markets. A detailed picture of the nemolizumab for atopic dermatitis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report along with a detailed description of the nemolizumab for atopic dermatitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the nemolizumab market forecast analysis for atopic dermatitis in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in atopic dermatitis.

Drug Summary

Nemolizumab (CD14152) is a subcutaneously administered monoclonal antibody that antagonizes IL-31RA, a cytokine that plays a key role in the pathogenesis of moderate-to-severe AD, thereby blocking IL-31 signaling on its effector cells, including peripheral neurons.

The drug was initially developed by Chugai Pharmaceutical and subsequently licensed to Galderma in 2016 – worldwide except Japan and Taiwan.

The drug is being developed by Maruho in Japan. In September 2016, Chugai Pharmaceutical and Maruho announced that they had entered into a license agreement. Under the agreement, Chugai granted Maruho a license for the development and marketing of nemolizumab for the skin disease area in Japan. Chugai will continue to be responsible for product manufacturing and supply of nemolizumab. Under the terms of the agreement, Chugai received an upfront and other payments from Maruho. The development and marketing of nemolizumab for pruritus in hemodialysis patients will be continued solely by Chugai.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the nemolizumab description, mechanism of action, dosage and administration, research and development activities in atopic dermatitis.

Elaborated details on nemolizumab regulatory milestones and other development activities have been provided in this report.

The report also highlights the nemolizumab research and development activities in atopic dermatitis across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around nemolizumab.

The report contains forecasted sales of for atopic dermatitis till 2032.

Comprehensive coverage of the late-stage emerging therapies for atopic dermatitis.

The report also features the SWOT analysis with analyst views for nemolizumab in atopic dermatitis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Nemolizumab Analytical Perspective by DelveInsight

In-depth Nemolizumab Market Assessment

This report provides a detailed market assessment of nemolizumab for atopic dermatitis in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

Nemolizumab Clinical Assessment

The report provides the clinical trials information of nemolizumab for atopic dermatitis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for atopic dermatitis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence nemolizumab dominance.

Other emerging products for atopic dermatitis are expected to give tough market competition to nemolizumab and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of nemolizumab in atopic dermatitis.

Our in-depth analysis of the forecasted sales data of nemolizumab from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the nemolizumab in atopic dermatitis.

Key Questions

What is the product type, route of administration and mechanism of action of nemolizumab?

What is the clinical trial status of the study related to nemolizumab in atopic dermatitis and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the nemolizumab development?

What are the key designations that have been granted to nemolizumab for atopic dermatitis?

What is the forecasted market scenario of nemolizumab for atopic dermatitis?

What are the forecasted sales of nemolizumab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available and how are these giving competition to nemolizumab for atopic dermatitis?

Which are the late-stage emerging therapies under development for the treatment of atopic dermatitis?